Page 1452 - Williams Hematology ( PDFDrive )

1426 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1427

732. Lekakis L, de Lima M: Reduced-intensity conditioning and allogeneic hematopoietic 760. Porter DL, Collins RH, Hardy C, et al: Treatment of relapsed leukemia after unre-
stem cell transplantation for acute myeloid leukemia. Expert Rev Anticancer Ther lated donor marrow transplantation with unrelated donor leukocyte infusions. Blood
8:785, 2008. 95:1214, 2000.
733. Blaise D, Vey N, Faucher C, Mohty M: Current status of reduced-intensity-conditioning 761. Bishop MR, Tarantolo SR, Pavletic ZS, et al: Filgrastim as an alternative to donor
allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 92:533, leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol
2007. 18:2269, 2000.
734. Schlenk RF, Hartmann F, Hensel M, et al: Less intense conditioning with fludarabine, 762. Trenschel R, Bernier M, Stryckmans P, et al: Complete remission following donor
cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unse- PBSC after low-dose cytarabine chemotherapy for early relapse of acute myelogenous
lected peripheral blood stem cell transplantation in elderly patients with leukemia. leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 19:381,
Leukemia 16:581, 2002. 1997.
735. Massenkeil G, Nagy M, Lawang M, et al: Reduced intensity conditioning and prophy- 763. Porter DL, Antin JH: Donor leukocyte infusions in myeloid malignancies: New strat-
lactic DLI can cure patients with high-risk acute leukaemia if complete donor chime- egies. Best Pract Res Clin Haematol 19:737, 2006.
rism can be achieved. Bone Marrow Transplant 31:339, 2003. 764. Cooley S, Weisdorf DJ, Guethlein LA, et al: Donor selection for natural killer cell
736. Giralt S, Anagnostopoulos A, Shahjahan M, Champlin R: Nonablative stem cell trans- receptor genes leads to superior survival after unrelated transplantation for acute
plantation for older patients with acute leukemias and myelodysplastic syndromes. myelogenous leukemia. Blood 116:2411, 2010.
Semin Hematol 39:57, 2002. 765. Elmaagacli A, Steckel NK, Koldehoff M, et al: Early human cytomegalovirus replica-
737. Maris MB, Niederwieser D, Sandmaier BM, et al: HLA-matched unrelated donor tion after transplantation is associated with a decreased relapse risk: Evidence for a
hematopoietic cell transplantation after nonmyeloablative conditioning for patients putative virus-versus-leukemia effect in acute myelogenous leukemia patients. Blood
with hematologic malignancies. Blood 102:2021, 2003. 118:1402, 2011.
738. Chakraverty R, Peggs K, Chopra R, et al: Limiting transplantation-related mortality 766. Czibere A, Bruns I, Kröger N, et al: 5-Azacytidine for the treatment of patients with
following unrelated donor stem cell transplantation by using a nonmyeloablative con- acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: A
ditioning regimen. Blood 99:1071, 2002. retrospective analysis. Bone Marrow Transplant 45:872, 2010.
739. Alyea EP, Kim HT, Ho V, et al: Impact of conditioning regimen intensity on outcome 767. Cunningham I: Extramedullary sites of leukemia relapse after transplant. Leuk Lym-
of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leu- phoma 45:1754, 2006.
kemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12:1047, 2006. 768. Murata M, Ishikawa Y, Ohashi H, et al: Donor cell leukemia after allogeneic periph-
740. Ringdén O, Labopin M, Ehninger G, et al: Reduced intensity conditioning compared eral blood stem cell transplantation: A case report and literature review. Int J Hematol
with myeloablative conditioning using unrelated donor transplants in patients with 88:111, 2008.
acute myeloid leukemia. J Clin Oncol 27;4570, 2009. 769. Reichard KK, Zhang QY, Sanchez L, et al: Acute myeloid leukemia of donor origin
741. Oran B, Giralt S, Saliba R, et al: Allogeneic hematopoietic stem cell transplantation after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic
for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syn- leukemia: Case report and review of the literature. Am J Hematol 81:178, 2006.
drome using reduced-intensity conditioning with fludarabine and melphalan. Biol 770. Shlush LI, Ilani NC, Ader R, et al: Cell lineage analysis of acute leukemia relapse
Blood Marrow Transplant 13:454, 2007. uncovers the role of replication-rate heterogeneity and microsatellite instability. Blood
742. Gyurkocza B, Storb, R, Storer BE, et al: Nonmyeloablative allogeneic hematopoietic cell 120:603, 2012.
transplantation in patients with acute myeloid leukemia. J Clin Oncol 38:2859, 2010. 771. Ding L, Ley TJ, Larson DE, et al: Clonal evolution in relapsed acute myeloid leukaemia
743. Alatrash G, de Lima M, Hamerschlak N, et al: Myeloablative reduced-toxicity i.v. revealed by whole-genome sequencing. Nature 481:506, 2012.
busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients 772. Estey E: Treatment of refractory AML. Leukemia 10:932, 1996.
with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth 773. Estey E, Kornblau S, Pierce S, et al: A stratification system for evaluating and selecting
decades of life. Biol Blood Marrow Transplant 17:1490, 2011. therapies in patients with relapsed or primary refractory acute myelogenous leuke-
744. Estey E, de Lima M, Tibes R, et al: Prospective feasibility analysis of reduced-intensity mia. Blood 88:756, 1996.
conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in 774. Burnett AK, Goldstone A, Hills RK, et al: Curability of patients with acute myeloid
elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic leukemia who did not undergo transplantation in first remission. J Clin Oncol 31:1293,
syndrome (MDS). Blood 109:1395, 2007. 2013.
745. Tallman MS, Dewald GW, Gandham S, et al: Impact of cytogenetics on outcome of 775. Stoiser B, Knöbl P, Fonatsch C, et al: Prognosis of patients with second relapse of acute
matched unrelated donor hematopoietic stem cell transplantation for acute myeloid myeloid leukemia. Leukemia 14:2059, 2000.
leukemia in first or second complete remission. Blood 110:409, 2007. 776. Lee S, Tallman MS, Oken MM, et al: Duration of second complete remission com-
746. Gale RP, Horowitz MM, Rees JK, et al: Chemotherapy versus transplants for acute pared with first complete remission in patients with acute myeloid leukemia. Leuke-
myelogenous leukemia in second remission. Leukemia 10:13, 1996. mia 14:1345, 2000.
747. Bacigalupo A, Lamparelli T, Gualandi F, et al: Allogeneic hemopoietic stem cell trans- 777. Kern W, Schoch C, Haferlach T, et al: Multivariate analysis of prognostic factors in
plants for patients with relapsed acute leukemia: Long-term outcome. Bone Marrow patients with refractory and relapsed acute myeloid leukemia undergoing sequential
Transplant 39:341, 2007. high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Rele-
748. Duval M, Klein JP, He W, et al: Hematopoietic stem-cell transplantation for acute leu- vance of cytogenetic abnormalities. Leukemia 14:226, 2000.
kemia in relapse or primary induction failure. J Clin Oncol 28:3730, 2010. 778. Estey EH: Treatment of relapsed and refractory acute myelogenous leukemia. Leuke-
749. Michel G, Boulad F, Small TN, et al: Risk of extramedullary relapse following allo- mia 14:476, 2000.
geneic bone marrow transplantation for acute myelogenous leukemia with leukemia 779. Leopold LH, Willemze R: The treatment of acute myeloid leukemia in first relapse: A
cutis. Bone Marrow Transplant 20:107, 1997. comprehensive review of the literature. Leuk Lymphoma 43:1715, 2002.
750. Blau IW, Basara N, Bischoff M, et al: Second allogeneic hematopoietic stem cell trans- 780. Alvarado Y, Tsimberidou A, Kantarjian H, et al: Pilot study of Mylotarg, idarubicin
plantation as treatment for leukemia relapsing following a first transplant. Bone Mar- and cytarabine combination regimen in patients with primary resistant or relapsed
row Transplant 25:41, 2000. acute myeloid leukemia. Cancer Chemother Pharmacol 51:87, 2003.
751. Christopeit M, Kuss O, Finke J, et al: Second allograft for hematologic relapse of acute 781. Revesz D, Chelghoum Y, Le QH, et al: Salvage by timed sequential chemotherapy in
leukemia after first allogeneic stem-cell transplantation from related and unrelated primary resistant acute myeloid leukemia: Analysis of prognostic factors. Ann Hema-
donors: The role of donor change. J Clin Oncol 31:3259, 2013. tol 82:684, 2003.
752. Shlomchik WD, Emerson SG: The immunobiology of T cell therapies for leukemias. 782. Wrzesień-Kuś A, Robak T, Lech-Marańda E, et al: A multicenter, open, non-
Acta Haematol 96:189, 1996. comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine),
753. Porter DL, Roth MS, Lee SJ, et al: Adoptive immunotherapy with donor mononuclear cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia: A
cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic report of the Polish Adult Leukemia Group (PALG). Eur J Haematol 71:155, 2003.
bone marrow transplantation. Bone Marrow Transplant 18:975, 1996. 783. Pastore D, Specchia G, Carluccio P, et al: FLAG-IDA in the treatment of refractory/
754. Porter DL: Donor leukocyte infusions in acute myelogenous leukemia. Leukemia relapsed acute myeloid leukemia: Single-center experience. Ann Hematol 82:231, 2003.
17:1035, 2003. 784. Roboz GJ, Knovich MA, Bayer RL, et al: Efficacy and safety of gemtuzumab ozogami-
755. Greinix NT: DLI or second transplant. Ann Hematol 81:S34, 2002. cin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 43:1951,
756. van Rhee F, Kolb HJ: Donor leukocyte transfusions for leukemic relapse. Curr Opin 2002.
Hematol 2:423, 1995. 785. Advani R, Saba HI, Tallman MS, et al: Treatment of refractory and relapsed acute
757. Berthou C, Leglise MC, Herry A, et al: Extramedullary relapse after favorable molec- myelogenous leukemia with combination chemotherapy plus the multidrug resistance
ular response to donor leukocyte infusions for recurring acute leukemia. Leukemia modulator PSC 833 (Valspodar). Blood 93:787, 1999.
12:1676, 1998. 786. Estey EH, Kantarjian HM, O’Brien S, et al: High remission rate, short remission dura-
758. Carlens S, Remberger M, Aschan J, Ringden O: The role of disease stage in the tion in patients with refractory anemia with excess blasts (RAEB) in transformation
response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combina-
Marrow Transplant 7:31, 2001. tion with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1:21, 1995.
759. Keil F, Prinz E, Kalhs P, et al: Treatment of leukemic relapse after allogeneic stem cell 787. Becker PS, Kantarjain HM, Appelbaum FR, et al: Clofarabine with high dose cyta-
transplantation with cytoreductive chemotherapy and/or second transplants. Leuke- rabine and granulocyte colony-stimulaing factor (G-CSF) priming for relapsed and
mia 15:355, 2001. refractory acute myeloid leukaemia. Br J Haematol 155:182, 2011.

Kaushansky_chapter 88_p1373-1436.indd 1427 9/21/15 11:02 AM